CSIMarket Company Name, Ticker, Industry, else..
 
Grifols Sa  (NASDAQ: GRFS)
Other Ticker:  
 
 
Price: $7.2900 $-0.31 -4.079%
Day's High: $7.38 Week Perf: -5.69 %
Day's Low: $ 7.22 30 Day Perf: -0.14 %
Volume (M): 589 52 Wk High: $ 9.96
Volume (M$): $ 4,291 52 Wk Avg: $7.75
Open: $7.38 52 Wk Low: $5.30



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) -
 Employees 24,000
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) 202
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 235

Grifols Sa
Grifols SA is a Spanish multinational pharmaceutical and chemical company. It specializes in the production of plasma-derived medicines, diagnostics systems, and medical devices. Grifols' main products include plasma-derived proteins for therapeutic use, such as immunoglobulins, albumin, clotting factors, and alpha1-antitrypsin. The company also provides blood collection and diagnostic equipment, as well as laboratory testing services. Grifols operates globally and has a strong presence in Europe, North America, and Asia. It is committed to improving the health and well-being of patients worldwide through its innovative healthcare solutions.


   Company Address: Avinguda de la Generalitat, 152-158 Barcelona 8174 CA
   Company Phone Number: 93 571 02 21   Stock Exchange / Ticker: NASDAQ GRFS


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABBV   -1.04%    
BMRN        2.84% 
REGN   -3.04%    
SNY        2.16% 
UTHR   -0.23%    
VRTX   -1.54%    
• View Complete Report
   



Clinical Study

Grifols, a global leader in the production of plasma-derived medicines, has recently received approval from...

Published Mon, Jul 29 2024 12:00 PM UTC

Expansion of XEMBIFY? Label in the U.S. Augments Treatment Options for Primary Humoral Immunodeficiencies Grifols, a global leader in the production of plasma-derived medicines, has recently received approval from the United States Food and Drug Administration (FDA) for an expanded label for XEMBIFY? (immune globulin subcutaneous human-klhw). This approval marks a significan...
Stocks on the Move

Grifols SA Thrives with Strong Stock Performance Amidst Acquisition Talks

Published Tue, Jul 16 2024 8:36 AM UTC

Grifols SA, a reputable Spanish pharmaceutical company specializing in blood plasma medicines, has been making waves in the market with its impressive stock performance. Despite recent allegations and discussions surrounding a potential takeover bid, Grifols shares have outperformed the market by 2.9% this month. This article explores the events that have unfolded for Grifol...
Management Announcement

Yimmugo's $1 Billion Sales Projection in the US Fuels Grifols' Expansion, but Efforts Need to Boost ROI for Sustained Growth

Published Mon, Jul 1 2024 10:01 AM UTC



Grifols, a leading global producer of plasma-derived medicines, has announced that its subsidiary, Biotest, anticipates generating approximately $1 billion in revenue from sales of its intravenous immunoglobulin (Ig) called Yimmugo over the next seven years in the United States. This positive forecast follows the recent approval by the Food and Drug Administration ...
Management Announcement

Grifols Sets New Strategic Path with Sale of Equity Stake and Alliance with Haier Group

Published Tue, Jun 18 2024 11:30 AM UTC


The agreement between Grifols and Haier Group signifies a significant development in the healthcare industry, with implications for both companies future growth and expansion. The deal has successfully obtained all necessary regulatory approvals and compliance confirmation from the Shenzhen Stock Exchange.
Grifols achieved a return on average invested assets (ROI) ...
Product Service News

Grifols Marks Milestone Anniversary as a Leading Manufacturer of Life-Saving Plasma-Derived Medicines at Clayton Facility

Published Thu, Apr 18 2024 1:30 PM UTC

Grifols Celebrates 50 Years of Manufacturing Life-Changing Plasma-Derived Medicines for Patients at Flagship Site in Clayton, N.C.BARCELONA, Spain, April 18, 2024 - Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company renowned for its pivotal contributions to the field of plasma-derived medicines, proudly commemorated the momentous 50th anniversary of its d...









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com